Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 26;67(3):103-108.
doi: 10.15585/mmwr.mm6703a5.

Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines

Kathleen L Dooling, Angela Guo, Manisha Patel, Grace M Lee, Kelly Moore, Edward A Belongia, Rafael Harpaz

Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines

Kathleen L Dooling et al. MMWR Morb Mortal Wkly Rep. .

Abstract

On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01B), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest were reported.

References

    1. Food and Drug Administration. Shingrix [package insert]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2017. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedPr...
    1. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20:748–53. 10.1111/j.1525-1497.2005.0150.x - DOI - PMC - PubMed
    1. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341–9. 10.4065/82.11.1341 - DOI - PubMed
    1. Oxman MN, Levin MJ, Johnson GR, et al.; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–84. 10.1056/NEJMoa051016 - DOI - PubMed
    1. Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract 2009;63:1386–91 .10.1111/j.1742-1241.2009.02089.x - DOI - PMC - PubMed

MeSH terms